Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're right, 32.5M of that OS increase is accounted for. 60M more is negligible compared to numbers we've seen the last couple years. Am a sleepy fox today.
Been dealing with nonstop work and life crises this year. Missed some big opportunities to capitalize on this run, but I'm happy to see price trending up. I feel you about the tightrope, the SAGA thing is a bit of a head scratcher that I wasn't at all expecting. Price has been moving very sharply upward, so I think it'll correct soon, but hopefully continue increasing in the big picture. 2 year chart so far looks to be forming a big bowl.
Some of the information you quoted doesn't look accurate. But I'd love to hear your reasoning why you think ENZC wouldn't sell subsidiaries.
It's interesting ENZC is moving to sell Biogenysis and Virogentics to Sagaliam at the same time ENZC increased A/S here in the pinks. On the one hand it's a possible fast track to Nasdaq GM for Chandra and those subsidiaries; on the other hand, the hype might support insiders dumping new shares. Increasing A/S would get negative hype if they did it without pairing it with exciting news. It looks savvy or sketchy depending on one's point of view.
There's been an increase in O/S of roughly 90 mil since March 2023. Float on otcmarkets still reflects the March 2022 total.
The ENZC management have real problems because there isn't anyway a Form 15 or Dark company like ENZC is going to sell two newly created empty subsidiaries for $250M - it will never happen.
Best wishes to you that it goes great and you have a smooth recovery!
https://www.amazon.com/dp/B0BW39P97W
The original link was wrapped with a URL shortener service. Those might be used for brevity, or to measure clickthrough statistics in every location shared.
I can't get IPF Immune to appear in an Amazon search either.
Totally agree.
If these guys wanted to remain in the shadows and keep their dealings so secretive, then they should have remained private. They are a publicly traded company and we’ve questioned many times here the line between progressing in silence and the fiduciary duty to shareholders. Majority of press releases for the past two years have been rehashed promises and lacked any real substance to them.
ENZC has been disclosing that they have partnerships with companies and universities, are under NDA(s), that drugs are being produced for trials, and that various trials are/were underway. Although the company's been frustratingly vague, are those disclosures enough to cover Pink sheet material events reportability?
I do think they may be holding off on going SEC reporting to avoid more stringent disclosure requirements surrounding material events. Avoiding uplist may be good or bad, since they could better obfuscate both progress and setbacks by staying Pink.
For ITV-1, we know Danhson was supposed to be making ITV-1 for trials by Clinic Design to get EMA approval, then Scendea was to assist in obtaining FDA approval once EMA approval was granted. (source)
For mAbs,
The Company's primary anti-HIV monoclonal antibody has been produced and successfully tested in vitro against multiple strains of the virus where it shows complete efficacy. The recombinant form of the parent antibody (necessary for patient therapy) has been successfully produced for the Company by Samsung Biologics. This recombinant antibody is currently undergoing efficacy testing in Europe. (source)
It's hard to know if they're anywhere near that timeline. ENZC has missed with other projections, and they don't seem to disclose setbacks in a timely manner, so I'd be careful counting on big news in March. But hopefully so, and agreed the video sounds good!
Dyno makes a good point about not seeing any IND filings yet. As far as I know, Regeneron's REGN14287 hasn't started trials either. Some folks think there may be a Regeneron/ENZC link, since Suraj Saggar worked as trial investigator for REGEN-COV mAb's, and joined ENZC's advisory board in early 2022. If ENZC is pedal to the metal trying to close a deal with Regeneron, they might move slower with things like IPF Immune or ITV-1. But we can't know if they don't communicate.
A hypothetical buyback sounds awesome, but so far ENZC hasn't shown anything on financials that would suggest they acquired any shares or had the capital to buy them.
A partner securing a position over 5% (~115M shares) sounds good too, but it doesn't totally gel with the PPS trending down for two years. Maybe, if there are enough sellers.
Looking forward to the next set of financials as well.
Minute 23 to minute 26 is a good listen. Video is from an ENZC presentation at the 2021 emerging growth conference.
It makes sense to avoid uplisting to a tier that has higher reportability requirements if there are deals or setbacks still unfolding they don't want to disclose. Though imo, extra accountability and accounting rigor would help the share price. Not being transparent about that stuff is very Pink.
As others noted too, maybe they're saving it for a PR firestorm.
QB requires timely disclosure of material news, good and bad.
Charts and TA
Just some observations in case anyone finds them useful.
I was kind of expecting this to double bottom before it had a real chance to reverse. That could still happen in the .02s or low .03s since the pattern has been for this to drop hard every 3-6 months. But this particular cycle, it's been spending a lot of time nearer the high side of its trading range.
What's different than past cycles? The company finished the audit and seems to be making progress on its first marketable product. We could also be seeing a dead cat bounce. (Temporary stall in a continuing downtrend.) A catalyst now could send this toward a dime+, otherwise there's some bearish signals on the weekly.
Daily chart:
Weekly chart:
Great response, thanks.
A bunch of stocks, including memestocks like Gamestop and A*C, ran big in 2021. Briefly, short sellers found themselves exposed to infinite risk. My speculation about MMs shorting intraday for micro-profits is how they might insulate themselves against a repeat and still be able to aggressively short sell.
Why would they stick with ENZC? Because traders believe in it. Always fresh money coming in.
Agreed that stronger buying pressure could help break the downtrend. Hoping to see something tangible/major from ENZC.
Weekly chart shows Dark Cloud Cover. I'm anticipating a confirmation candle this week, ending the week where we are now. (.0500 to .0545 ish)
Is it possible for a client to buy shares through one MM and sell through another? That could explain INTL buying shares higher than they sold for. The client would take the loss, if any.
Finishing the audit improved ENZC's credibility a lot. But until Charles gets the company SEC reporting and uplisted to QB or QX, I feel there's still a credibility issue. Lots of big talk, delayed/underwhelming results, lots of 'trust the plan' and not enough corporate transparency. JMO
How could ENZC buy back shares without the money or the shares appearing in the financials?
The pattern you described with JANE and PUMA looks like market manipulation. For those who can short sell, it seems it'd be profitable to ride this down to the bottom. MMs could use algos to sell at optimal moments, ladder their sells, and cover intraday to minimize risk (if so, that behavior might show up in short volume and not short interest). Those micro-profits might be a motive for driving this down, not MMs knowing insider info or working trades on behalf of the company.
ENZC might break the downtrend by delivering big results, improving investor confidence via accountability so more investors are willing to long hold, and/or getting away from manipulative MMs by uplisting. Chart looks to be bowling out too, so it might run later if there's no more profit to be made shorting it.
Anyone aware of the settlement agreement with Livingston would have known that starting in 2018 hundreds of millions of shares would flood the market. They would also have known per the terms of the settlement, Livingston wasn't allowed to hold many of the shares.
Right after Livingston finished liquidating, a flow of company news suddenly appeared and made for profitable trading for anyone who'd accumulated in the low trips.
Each new issuance under the 3(a)(10) increased the float in the same years and by the same number of shares as the Federal Court approved settlement. This settlement required the original shares be issued with no restrictive legend. The total increase in original issued shares and public float during this two-year period was 1,165,021,256. Total float at December 31, 2020 was 1,670,830,512. Livingston Asset Management held no position in ENZC shares at December 1, 2020. The shares from the 3(a)(10) and fee note transferred from Livingston Asset Management to the general public at prices presumably below .0145 by open market sales.
Page 1 https://www.otcmarkets.com/otcapi/company/financial-report/323613/content
At no time may Livingston beneficially own more than 9.99% of the Company’s outstanding common stock.
Page 9 https://www.otcmarkets.com/otcapi/company/financial-report/355547/content
The Crooked Mark Makers sold all their stolen shares at the top to cash in Millions at retail investor's expense who sold at a loss prior to the run leading up to January 2021.
Only with money you can afford to lose - if it's not ENZC, price could plummet instantly.
Still, an exciting possibility. :) There's a quote in the bottom right of the first slide: "Anticipate initiating REGN14287 clinical trial in 2023, pending regulatory discussions."
In my opinion, I would get in now as if a PR like that hit price would skyrocket instantly
Yeah it's a little tangly.
- It would seem all profit would flow up to the parent entity (unnamed European pharma company), and Enzolytics says the deal gives Enzolytics 50% of "profit derived from sales in the Licensed Territory" without specifying ITV-1 profits only. They left it ambiguous.
- How could Enzolytics have 50% ownership across the board but not 50% revenue sharing across the board?
- If the revenue sharing part of the deal was indeed for ITV-1 revenue only, there would be no revenue since ITV-1 isn't for sale yet.
If instead ENZC would share all profits from this entity, here are some possibilities:
- ENZC should already have been showing revenue and its accounting is bad.
- That parent entity is making zero revenue and thus has none to share.
- That part of the agreement hasn't taken effect yet. ( "Enzolytics will receive $1 Million USD and 50% ownership in the Licensing Entity valued at $8 Million.")
Will be curious to see how it transpires.
I think their agreement is for ITV-1, not IPF. If I'm reading correctly, Enzolytics shares 50% ownership of the parent pharma company (which one?) that owns "a pharmaceutical plant in Eastern Europe", and Enzolytics shares 50% profit from ITV-1 sales in the licensed territory.
Looks like they're not sharing profit from all products sold by that pharma company. Just ITV-1. Since ITV-1 is not for sale in the licensed territory, Enzolytics wouldn't be reporting revenue from this agreement currently.
Issuance of Distributorship for India and multiple Eastern European Countries. On May 12, 2021, the Company granted a distributorship license to a European pharma entity giving it the right to distribute the Company's anti-HIV-1 therapeutic ITV-1 in the countries of India, Pakistan, UAE, Indonesia, Philippines, Nigeria, Benin and Togo, Kenya, Tanzania, Rwanda, Libya, Uganda, North Sudan, Egypt, Morocco, and Tunisia. The Licensing Entity is the owner of a pharmaceutical plant in Eastern Europe. Pursuant to the Agreement, Enzolytics will receive $1 Million USD and 50% ownership in the Licensing Entity valued at $8 Million. The License is granted with a commitment by the Licensee to sale and distribute the ITV-1 therapeutic in the Licensed Territory. In addition, the Licensing Entity has invested $2 Million USD in the Company in exchange for Company Preferred Series E stock bringing to the Company $3 Million in cash plus a 50% ownership in the Licensing Entity. This agreement will result in establishing a committed partner for sale and distribution of the Company's ITV-1 therapeutic in the Licensed Territory as well as 50% ownership in Licensee and its profit derived from sales in the Licensed Territory. (Page 13 of Annual Report - Amended Annual Disclosure Statement 2021)
As part of the agreement whereby ENZC became 50% owner of the Bulgarian Entity in a joint venture, International Medical Partners, LLC (IMPL) the Company issued 2,000,000 shares of Series B Preferred Stock relating to the investment in IMPL for $800,000 and granted a distributorship for ITV-1 in exchange for which IMPL shall fund certain costs for ITV-1 European Medical Agency permitting of ITV-1. The agreement was signed March 16, 2021. The shares of Series B were issued on August 11, 2021. The territories covered by the distribution agreement are Russia, Georgia, Ukraine, Moldova, Belarus, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Estonia, Latvia and Lithuania. (Page 18 of Annual Report - AMENDED FINANCIALS AND FOOTNOTES DECEMBER 31, 2021)
It looked to me like they met most of the requirements for QB.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170808262
The biggest roadblock I see is they would have to be transparent about material events, which is a 180 from their current approach with NDAs.
Same here, haha.
Good luck to you.
I add it drops, no fail.
I was looking at OTC uplisting requirements last night. With the audit done, wouldn't uplisting be an imminent catalyst? And I'd think they'd aim for OTC uplists before NYSE or Nasdaq. Anything to get out of the pinks!
From what I could see, ENZC can't uplist to QX until they get a lot more revenue, or increase net tangible assets.
Net Tangible Assets:
$5mm: Less Than 3 Years Operations
$2mm: 3+ Years Operations
OR
Revenue:
$6 million average for last 3 years
https://www.colonialstock.com/otc-listings.htm#otcqx
Provide timely disclosure of material news.
https://www.colonialstock.com/otc-listings.htm#otcqb
Corporate Governance (Required for Alternative Reporting Standard Only). Alternative Reporting Companies are required to meet the corporate governance standards outlined below: a. Have a board of directors that includes at least two Independent Directors; and b. Have an Audit Committee, a majority of the members of which are Independent Directors.
https://www.otcmarkets.com/files/OTCQB_Standards.pdf (bottom of page 2)
IPF Immune for sale and audit finished since then. Would be surprising to see this back in the .02's
I disagree, measuring relative to the last 30 days shows clearly more activity in the last few days, which is an interesting data point when paired with other indicators. It doesn't prove anything, just more interest than there's been.
I do agree that we won't necessarily see a massive volume uptick before this makes a bigger move. For example, ENZC has suggested it would uplist after finishing the audit. The audit is done, and I haven't heard anything about uplist though they may already have submitted papers. If we wake up one morning and this is suddenly QB, pps might spike suddenly.
Volume's been 100+% of the 30 day average (which is 4.65M) for three of the last four days. Doesn't mean anything by itself, but it's interesting to see.
Shorting and covering in the same day would show up as short volume, but not short interest, yes?
There are 2,313,596,368 shares in ENZC's float. Plenty there for algos to borrow, push the price down, make smaller profits more frequently and not overexpose sellers to risk.
Also this is a good post, thanks! https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162380361
8.6+ million shorts sold today, sounds like somebody's expecting it to come back down.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170738449
Hit one of the falling wedge profit targets today. It could go higher to .058 or maybe .064 if the market is still excited about the news.
In a forward split, more shares are created while the market cap remains the same. So no value is gained or lost but each share is worth less money than before.
Normally, Nasdaq uplist minimum bid price is $4/share. Is that the same for Nasdaq First North Growth Market? Will creating more shares make it harder to uplist?
https://www.investopedia.com/ask/answers/what-stock-split-why-do-stocks-split/
https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5500-series
Look at that volume. :)
It's yet to be seen whether everyone will get their shipments or if there'll be backorders/delays while ENZC produces more inventory. So far I see various comments that the delays are pretty brief. Good luck with your order!
They'll catch up eventually since they haven't done marketing yet:
Demand is now nil since IPF and onelava don't exist outside of shareholders. (post)
No problem. Investopedia is a great reference, and Youtube is a wealth of free knowledge. Many different teaching styles out there, so pick a topic, watch a bunch of different presentations, and look for the common ground. Good luck!
"False Breakout" is a TA concept. Not to be confused or conflated with "Pink Sheet traders should ignore its significance".
False breakouts occur when the price breaks past a certain level (support, resistance, triangle, trend line, etc.) but don't continue to accelerate in that direction. Instead, what you might've seen was a short spike followed by the price moving back into its trading range.
What a logic leap. Falling wedge "analysis" failed because so far the falling wedge pattern didn't break to the upside.
Newsflash, sometimes they don't.
Here's a good start to familiarize yourself with what falling wedges are and how they work.
https://www.investopedia.com/terms/w/wedge.asp
If you still believe the analysis failed, I'm all ears. Show me three examples of where it "failed"!
(It would actually be great to get feedback if I missed something. That's how I learn too.)
Briefly popped out of that falling wedge, but fell right back inside. The action looks to have served as a false breakout / bull trap and makes the overall chart a lot more bearish.
- Falling wedges have a decent track record of breaking to the upside. But they don't always.
- We're almost at the apex, so it's time for the market to move.
- Note how this gapped higher on Monday. The gap may have helped pull the market back.
- Can we expect any catalyzing news? ENZC seemed focused on long term plans with their latest PR.
- Why would there be another, stronger breakout right after the first one fizzed out?
For this to have been more bullish, I'd have liked to see yesterday's close be around .0435 so the candle would look to be resting atop the wedge. That would have given it a chance to springboard higher today. Instead, falling back into the wedge area suggests bulls are exhausted or unwilling to add more cash. Waiting for today's candle, and probably tomorrow's also, to close red to confirm. (Bulls might rally after they fill the gap.)
https://www.investopedia.com/terms/w/wedge.asp
Daily intraday. Dark blue is 200 day moving average.
That's a great PR, thanks for sharing. To me it reads like there's a lot of cool stuff in the pipeline, but gears are turning slow enough that most of the big announces would happen next year if stuff goes according to plan. No mention of audit progress or uplist, but that's more market-focused and might be something to present elsewhere.
All this red on the ticker could be flippers who were hoping for bigger IPF Immune launch news. So far it's not unusually high volume, just a lot of selling.
Given these web traffic stats, it would appear OneLavi was an unknown before ENZC started working with them.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168524511
On Twitter I'm sure there were some new eyes-on as excited investors shared that product photo and the $ENZC symbol over the weekend & today. Still needs a proper marketing campaign to reach people who aren't also penny investors.
Edit: just for grins, I reran the same search on the same site so we could compare with Pugsieboy's post from April. 79 visits per month from March became 325 by November. Will be fun to see December's numbers whenever they come in, probably spiked pretty hard today.
None taken, and you're right.
Between the company's own ambiguity when communicating goals and timelines, and what people want to believe about them, it's easy to get misaligned expectations.
Thanks a bundle for your L2 insights this morning!
Political discussion is generally off-topic. Fauci and NIH are part of this company's DD, but discussion of politics itself tends to derail.
https://ihwiki.advfn.com/index.php?title=Handbook#Off_Topic
Fauci and Cotropia fighting over the Clone 3 patent says a lot about its potential. (At least as the science was seen in 1999)
Right. That's still definitely a flag.
I noticed Enzolytics has watered down the language describing IPF. Whereas before it was an "immune modulator" that stimulated the immune system, now it's a "nutritional dietary supplement that supports the immune system". So perhaps there was a regulatory issue. (Though that's not what they said in the June quarterly.)
It's tough because they could be bullshitting us by implying there's strong demand (whatever that means), OR telling us what they can without disclosing real contract details and commitments they've already landed. That kind of ambiguity has been the carrot on the stick with ENZC. Given their track record so far, I'd err on the side of them bullshitting us. But I'd love to be wrong.
Not selling a single bottle after tweeting photos of the first shipment is pretty sus though.
Hopefully so! They've had two ECRM conventions to get it in front of prospective retailers.
I try to keep expectations realistic, and I've generally counted what they said about "production capability" as a cop out for a product offering they were totally unprepared to make earlier this year.
But what if they really did have unexpected demand from national retailers at ECRM? Things could get interesting fast.
Enzolytics IPF Immune will be available in numerous sales outlets throughout the U.S. Delays in producing sufficient quantiles for the market are being addressed. These delays have provided time for increasing production capability to meet demand. The company’s market research has indicated significant demand for IPF Immune.
It should at least create a temporary pop in PPS. The investors watching ENZC closely are excited, and rightfully so, but there's been no advertising I'm aware of and OneLavi isn't exactly a high profile storefront. How will the rest of the world find it? (Besides word of mouth.) The trading setup seems ripe for a quick flip.
But regardless, if OneLavi actually starts selling IPF Immune tomorrow, that's some welcomed progress and a milestone met.